Bringing innovation to clinical trial design
By Richard Moscicki, M.D. | April 23, 2018
Clinical trials are critical to the discovery and development of innovative medicines that enable patients to live longer, healthier lives. As the biopharmaceutical industry works to identify,...
Read More
Spending on medicines grew less than one percent in 2017
By Holly Campbell | April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...
Read More
A new era in Alzheimer’s innovation
By Andrew Powaleny | April 19, 2018
After heart disease and cancer, Alzheimer’s disease and dementia are the leading cause of death for seniors, responsible for one out of every three deaths. Today, the disease devastates the minds...
Read More
New report shows over 500 medicines in development for neurological disorders
By Andrew Powaleny | April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....
Read More
Video: Barriers to results-based contracts
By Katie Koziara | April 17, 2018
Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these...
Read More
Patients pay the price when hospitals mark up cancer medicines
By Joe Vandigo | April 5, 2018
Two studies released last month reveal how hospitals across the country mark up the price of medicines and deliver a growing share of provider-administered medicines, resulting in higher costs...
Read More
PPA celebrates 13 years of helping patients access their medicines
By Hannah Mooney | April 5, 2018
As of 2018, 13 is no longer an unlucky number, especially when it comes to health. This April, the Partnership for Prescription Assistance (PPA) is celebrating 13 years of connecting people who...
Read More
Advance price notification: A transparency measure that fails patients
By Saumil Pandya and Emily Donaldson | March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...
Read More
340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?
By Nicole Longo | March 28, 2018
The once little-known 340B drug discount program, which was designed to help low-income, uninsured or otherwise vulnerable patients access prescription medicines at safety-net facilities, is now a...
Read More
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
By Holly Campbell | March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...
Read More
Medicare Monday (100)
340B Spotlight (33)
Cost & Consequence (0)
